X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs TTK HEALTHCARE - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES TTK HEALTHCARE PIRAMAL ENTERPRISES/
TTK HEALTHCARE
 
P/E (TTM) x 8.1 18.4 44.3% View Chart
P/BV x 1.5 6.0 24.4% View Chart
Dividend Yield % 1.1 0.5 230.1%  

Financials

 PIRAMAL ENTERPRISES   TTK HEALTHCARE
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
TTK HEALTHCARE
Mar-14
PIRAMAL ENTERPRISES/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3,083663 464.7%   
Low Rs1,902399 476.7%   
Sales per share (Unadj.) Rs589.7535.6 110.1%  
Earnings per share (Unadj.) Rs284.015.9 1,781.2%  
Cash flow per share (Unadj.) Rs310.520.0 1,550.6%  
Dividends per share (Unadj.) Rs25.004.00 625.0%  
Dividend yield (eoy) %1.00.8 133.2%  
Book value per share (Unadj.) Rs1,467.0137.6 1,066.0%  
Shares outstanding (eoy) m180.277.77 2,320.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.21.0 426.2%   
Avg P/E ratio x8.833.3 26.3%  
P/CF ratio (eoy) x8.026.5 30.3%  
Price / Book Value ratio x1.73.9 44.0%  
Dividend payout %8.825.1 35.1%   
Avg Mkt Cap Rs m449,3324,127 10,886.5%   
No. of employees `0006.81.7 400.6%   
Total wages/salary Rs m19,881607 3,277.5%   
Avg. sales/employee Rs Th15,535.62,436.7 637.6%   
Avg. wages/employee Rs Th2,905.4355.2 818.1%   
Avg. net profit/employee Rs Th7,482.572.5 10,314.9%   
INCOME DATA
Net Sales Rs m106,3104,162 2,554.4%  
Other income Rs m2,59561 4,240.7%   
Total revenues Rs m108,9064,223 2,578.9%   
Gross profit Rs m51,599197 26,178.9%  
Depreciation Rs m4,77332 15,057.7%   
Interest Rs m29,78330 99,608.7%   
Profit before tax Rs m19,638197 9,983.6%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,76473 -39,511.3%   
Profit after tax Rs m51,203124 41,325.9%  
Gross profit margin %48.54.7 1,024.8%  
Effective tax rate %-146.537.0 -395.8%   
Net profit margin %48.23.0 1,617.8%  
BALANCE SHEET DATA
Current assets Rs m118,1541,629 7,254.5%   
Current liabilities Rs m462,2601,058 43,700.1%   
Net working cap to sales %-323.713.7 -2,359.6%  
Current ratio x0.31.5 16.6%  
Inventory Days Days2730 89.3%  
Debtors Days Days4734 138.5%  
Net fixed assets Rs m113,727556 20,443.5%   
Share capital Rs m36178 464.0%   
"Free" reserves Rs m264,093878 30,068.7%   
Net worth Rs m264,4541,069 24,731.5%   
Long term debt Rs m242,206159 152,618.8%   
Total assets Rs m726,8342,399 30,292.3%  
Interest coverage x1.77.6 21.9%   
Debt to equity ratio x0.90.1 617.1%  
Sales to assets ratio x0.11.7 8.4%   
Return on assets %11.16.4 173.8%  
Return on equity %19.411.6 167.1%  
Return on capital %10.318.5 55.9%  
Exports to sales %00.8 0.0%   
Imports to sales %01.4 0.0%   
Exports (fob) Rs mNA33 0.0%   
Imports (cif) Rs mNA58 0.0%   
Fx inflow Rs m15,11033 45,927.1%   
Fx outflow Rs m4,29863 6,800.9%   
Net fx Rs m10,813-30 -35,696.6%   
CASH FLOW
From Operations Rs m-159,666127 -126,118.4%  
From Investments Rs m-17,677-146 12,107.7%  
From Financial Activity Rs m186,50322 851,609.6%  
Net Cashflow Rs m9,3643 374,572.0%  

Share Holding

Indian Promoters % 52.9 65.4 80.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 3.7 108.1%  
FIIs % 26.6 5.2 511.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 25.8 64.0%  
Shareholders   93,274 12,723 733.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   ALEMBIC LTD  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Capital Goods & Banking Stocks Lag(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is down 1.2%.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Nov 13, 2018 10:53 AM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS